首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 109 毫秒
1.
在血吸虫病疫区使用护肤涂剂以防尾蚴感染,是血防工作的重要课题。几十年来曾筛选过大量配方,建立过多种活体筛选模型,然未能投入实用。提示筛选的三个环节即:高效主药、合理配方和筛选模型缺一不可。吡喹酮问世以后,已被国内外公认为最好的抗血  相似文献   

2.
目的:设计一种基于深度学习的BERT-TextCNN模型,用于临床试验筛选短文本的自动化识别与分类。方法:调研文本分类的常见算法,从中国健康信息处理会议开发的临床试验中筛选短文本分类数据集,比较分析BERT-TextCNN模型、BERT模型和TextCNN模型的性能差异。结果:BERT-TextCNN模型的文本分类平均F1值为82.39%,相较于单纯使用BERT模型和TextCNN模型进行文本分类的性能分别提升了1.81%和9.02%。结论:基于BERT-TextCNN模型的临床试验筛选短文本分类方法有效,为今后相关医学领域的研究和临床试验筛选短文文本自动化系统开发提供了一定的参考。  相似文献   

3.
目的 对养肤乳剂精华素防晒性能进行评价与筛选。方法 紫外分光光度薄膜法。结果 在紫外线屏蔽方面,配方中沙棘油与纳米级ZnO有拮抗作用,橄榄油与纳米级ZnO有促进作用。结论 作为防晒产品,如配方中有沙棘油,不宜配入纳米级ZnO,橄榄油与纳米级ZnO复配在紫外线屏蔽方面有促进作用,可作为产品的基础配方进一步研究。  相似文献   

4.
利用生物粘附技术,将冰硼散剂改制成具有缓释、定位、单向释药特性的冰硼贴片,并以生物粘附时限为指标,从国产原料中筛选粘附剂、优化粘附剂配方;研究了冰硼贴片释药性能和咽喉用药的方法。  相似文献   

5.
冰硼贴片及其制备工艺的研究   总被引:9,自引:0,他引:9  
利用生物粘附技术,将冰硼散剂改制成具有缓释、定位、单向释药特性的冰硼贴片,并以生物粘附时限为指标,从国产原料中筛选粘附剂、优化粘剂配方;研究了冰硼贴片释药性能和咽喉用药的方法。  相似文献   

6.
经较详尽的试验对比,钢纤维增强的摩阻材料的摩擦学性能和机械性能,都优于硅酸铝纤维和无碱玻璃纤维增强的材料。提供了利用正交设计法筛选配方的方法,得到优化的半金属摩阻材料的配方。利用近代表面分析工具对半金属摩阻材料的表面和磨屑进行观察分析,并探讨了磨屑的形成机理。  相似文献   

7.
目的 探讨赤芍配方颗粒与赤芍饮片对急性血瘀大鼠抗凝功能的药理等效性。方法 大鼠灌胃给药不同剂量赤芍配方颗粒及同批次饮片煎液,复制急性血瘀模型后检测APTT、PT、TT,计算其抑制率并进行主成分分析。根据抑制率主成分建立曲线回归模型,确定合适的量效回归方程。比较两药等效应剂量及等剂量效应,分析两药的药理等效性。结果 模型组大鼠APTT、PT及TT均较空白组显著下降(P<0.01或P<0.05)。赤芍配方颗粒各剂量组APTT均较模型组显著升高(P<0.01或P<0.05);赤芍饮片2~8倍剂量组APTT较模型组显著升高(P<0.01或P<0.05)。赤芍配方颗粒及饮片8倍剂量组PT较模型组显著升高(P<0.05)。赤芍配方颗粒8倍剂量组TT较模型组显著升高(P<0.01)。根据剂量-效应进行曲线拟合后选择最合适的量效曲线方程,根据方程计算等效应剂量及等剂量效应,回归方程分别为:赤芍配方颗粒(g生药·kg-1)=0.382 1×DEE赤芍饮片(g生药·kg-1)+0.160 1及EED赤芍配方颗粒(%...  相似文献   

8.
不吸水链霉菌是从土壤中筛选出的一株放线菌,其代谢产物具有广谱抗真菌作用。本文重点筛选了该链霉菌菌种培养基和发酵培养基,对培养基的配方、培养条件和培养时间进行了摸索,以期获得高效价的SAMP。  相似文献   

9.
小艾  雪蛟 《健康之友》2007,(7):146-147
这是个“性价比时代”,从避孕套到车,都要对性能和价格进行多番考量。挑选男人也不例外,每个男人都有自己的性价比;“性”代表品质和优势,“价”这里指代价,即女人要获得这个男人所付出的代价或者受伤指数。[编者按]  相似文献   

10.
袁凯  吴萍 《医学研究杂志》2010,39(10):115-118
目的 对香菇多糖口腔膜剂的制备工艺进行研究,并筛选出最佳处方.方法 先对预实验得出的处方进行筛选,再以黏附力、溶解性作为评价指标进行综合评价,筛选出最佳膜剂配方.结果 通过对各配方比较得出最佳配方:聚乙烯醇3 6g,羧甲基纤维素钠0.4g,甘油0.5ml.结论 根据最佳处方制备的口腔膜剂,在黏附性、溶解性方面符合要求,而且外观也比较理想.  相似文献   

11.
OBJECTIVES: To re-evaluate the cost effectiveness of treating hepatitis C virus (HCV) infection with interferon alfa (IF alpha) in Australia, taking into account changes in clinical practice. DESIGN: A decision-analytic method (Markov model) was used to simulate the costs and effects of 6 months and 12 months of treatment with IF alpha versus no treatment (conventional management). Both costs and effects were modelled over 30 years. DATA SOURCES: Published meta-analysis of the effectiveness of treatment, professional judgement about treatment protocols, scheduled medical fees, diagnosis-related costs for hospital admission, and a literature search for quality-of-life weights. PATIENTS: A hypothetical cohort of 1000 patients with chronic HCV infection aged 40 years at the start of treatment. MAIN OUTCOME MEASURES: Incremental costs per life-year gained and per quality-adjusted life-year (QALY) gained. RESULTS: Compared with no treatment, IF alpha treatment for 6 months results in an extra 94.2 life-years or 320.1 QALYs at an extra cost of $1.8 million (after discounting at 3%) in a cohort of 1000 patients. Discounted cost per life-year gained is $19,110, which is about a quarter of the cost reported in 1994. The discounted cost per QALY gained is $5625. Extended treatment for another 6 months results in an additional 89.0 life-years saved or 170.8 QALYs gained at an incremental discounted cost of $15,835 per life-year gained and $8250 per QALY gained. CONCLUSIONS: The cost effectiveness of IF alpha treatment for HCV infection has improved as a result of better patient selection, cost reductions and enhanced effectiveness of extended treatment. The results are sensitive to assumptions made about quality of life and the discount rate.  相似文献   

12.
曾照秋 《中外医疗》2013,32(16):15-16
目的探讨左旋氨氯地平和氯沙坦钾在原发性高血压中的成本效果。方法选择该院原发性高血压患者100例,上述患者随机分为观察组和对照组。观察组给予苯磺酸左旋氨氯地平治疗,对照组给予氯沙坦治疗。评定两组临床效果,分析其成本效果。结果观察组总有效率(95.0%)与对照组总有效率(92.5%)比较,差异无统计学意义(P〉0.05)。观察组成本为158.6元,效果为0.96,成本效果为165.2。对照组成本为328元,效果为0.94,成本效果为348.9。观察组成本效果低于对照组。结论苯磺酸左旋氨氯地平治疗原发性高血压优于氯沙坦,值得借鉴。  相似文献   

13.
目的:评价善得定和垂体后叶素治疗肝硬化上消化道出血的药物疗效与治疗成本。方法:69例肝硬化上消化道出血病人随机分为善得定治疗组、垂体后叶素对照组,运用药物经济学成本-效果比进行分析。结果:治疗组的平均止血时间为27.48h,总有效率为91.43%,成本-效果比为14.27;对照组平均止血时间为36.44h,总有效率为82.35%,成本-效果比为9.03。结论:肝硬化上消化道出血的治疗可首选成本一效果比较低的垂体后叶素,如效果不佳及时更换善得定治疗。  相似文献   

14.
目的:评价帕珠沙星与左氧氟沙星治疗急性细菌性感染的成本-效果。方法:查阅文献,选择分别用帕珠沙星(A组)与左氧氟沙星(B组)治疗急性细菌性感染的病例240例,运用药物经济学成果-效果分析法进行分析和评价。结果:A组、B组临床总有效率分别为98.3%和96.7%;两组的成本分别为(4268.32±645.88)元、(1467.84±197.38)元;以临床总有效率计:A组、B组成果-效果比分别为43.42±6.57、15.18±2.04;A组相对于B组的增量成本-效果比为1750.30。结论:与帕珠沙星比较,左氧氟沙星治疗急性细菌性感染更具成本-效果优势。  相似文献   

15.
BACKGROUND: Schizophrenia afflicts approximately 0.7% of Mexican citizens during their lifetime. This study explored whether the difference in clinical efficacy and safety between atypical antipsychotics and conventional neuroleptics results in decreases in use and cost of medical services in Mexico, offsetting the higher price of atypical antipsychotics. METHODS: A U.S. decision analytic Markov model was adapted for use in Mexico to determine cost-effectiveness of treatments and outcomes that Mexican patients with schizophrenia may experience over a 5-year period when treated with olanzapine, haloperidol, or risperidone. Model parameter estimates were based on clinical trial data, published medical literature, and where needed, clinician judgment. Direct medical costs were incorporated into the model and outcomes were estimated using lack of relapse and clinical outcomes based on the Brief Psychiatric Rating Scale (BPRS) as effectiveness indicators. All costs are reported in Mexican pesos. RESULTS: Over a 5-year period, the cost of treating schizophrenia ranged from 196,620 pesos per patient initiating therapy with haloperidol to 226,670 pesos per patient beginning therapy with risperidone. Olanzapine was estimated to have slightly better non-relapse and BPRS-based effectiveness outcomes, but comparative total medical costs compared to risperidone. Patients receiving olanzapine experienced 13 and 2% fewer relapses compared with patients on haloperidol and risperidone, respectively. The 5-year incremental cost-effectiveness ratio of olanzapine compared with haloperidol was 52,740 pesos per improved patient, BPRS-based outcome and 212,540 pesos per avoided relapse. Sensitivity analyses indicated the model was sensitive only to changes in drug costs. CONCLUSIONS: Compared with haloperidol, olanzapine therapy results in improved symptoms, fewer relapses, and is cost-effective, even with conservative values for key model parameters. Olanzapine results in slightly improved patient outcomes and comparable costs compared with risperidone.  相似文献   

16.
目的评价头孢唑啉与头孢硫脒两种抗生素治疗小儿肺炎的成本效果比,为临床治疗方案的筛选提供药物经济学依据。方法选取2011年1月~2012年1月我院收治的符合纳入标准的肺炎患儿共100例,随机分为A、B两组,A组采用头孢唑啉治疗,B组采用头孢硫脒治疗,运用成本效果分析方法评价两种给药的药物经济学效果,并进行敏感度分析。结果两组方案的有效率分别为90%、96%;病原菌清除率分别为90%、92%;两组总有效率、病原菌清除率比较均无显著差异。两组人均费用分别为2019.39元、2347.50元.两组每增加一个单位效果其增加的成本分别为22.44元、24.45元,B组费用均稍高于A组。敏感度分析显示经济学分析结果稳定。结论小儿肺炎患者使用头袍畔啉、头袍硫眯均可获得良好疗效,从药物绎济学角席分析,头孑60I琉眯更为绎济,律议优先采用。  相似文献   

17.
2型糖尿病酮症酸中毒专科诊疗路径应用的评价研究   总被引:7,自引:0,他引:7  
目的 评价所建立的适用于我国城市医院患者的2型糖尿病专科诊疗路径的效果、效益、可行性和可推广性。方法 采用历史对照方法和个人深入访谈,对所建立的专科诊疗路径进行评价。结果 实施2型糖尿病酮症酸中毒专科诊疗路径能减少患者的住院天数、降低医疗费用,同时提高了患者对医疗服务的满意度。结论 2型糖尿病酮症酸中毒专科诊疗路径作为一个疾病管理模式具有一定的成本效益。  相似文献   

18.
目的:评价托烷司琼与格拉司琼联合甲氧氯普胺预防化疗所致恶心、呕吐的治疗效果及成本-效益比。方法:收集2012年1月至2012年11月经病理学和细胞学证实的恶性肿瘤(食管癌、鼻咽癌)80例,随机分为A组40例、B组40例,分别应用托烷司琼及格拉司琼联合甲氧鲁普胺预防化疗所致恶心、呕吐,观察止吐效果并进行成本-效益分析。结果:A、B两组止吐有效率分别为92.5%和87.5%(P>0.05);成本/效益比分别为2.06和0.70。结论:托烷司琼与格拉司琼联合甲氧氯普胺预防化疗所致恶心、呕吐的疗效相似,但后者成本-效益比好。  相似文献   

19.
Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1   总被引:2,自引:0,他引:2  
BACKGROUND: More than one million individuals in Mexico are infected with hepatitis C virus (HCV), and 80% are at risk for developing a chronic infection that could lead to hepatic cirrhosis and other complications that impact quality of life and institutional costs. The objective of the study was to determine the most cost-effective treatment against HCV among the following: peginterferon, peginterferon plus ribavirin, peginterferon plus ribavirin plus thymosin, and no treatment. METHODS: We carried out cost-effectiveness analysis using the institutional perspective, including a 45-year time frame and a 3% discount rate for costs and effectiveness. We employed a Bayesian-focused decision tree and a Markov model. One- and two-way sensitivity analyses were performed, as well as threshold-oriented and probabilistic analyses, and we obtained acceptability curves and net health benefits. RESULTS: Triple therapy (peginterferon plus ribavirin plus thymosin alpha-1) was dominant with lower cost and higher utility in relationship with peginterferon + ribavirin option, peginterferon alone and no-treatment option. In triple therapy the cost per unit of success was of 1,908 [USD/quality-adjusted life years (QALY)] compared with peginterferon plus ribavirin 2,277/QALY, peginterferon alone 2,929/QALY, and no treatment 4,204/QALY. Sensitivity analyses confirmed the robustness of the base case. CONCLUSIONS: Peginterferon plus ribavirin plus thymosin alpha-1 option was dominant (lowest cost and highest effectiveness). Using no drug was the most expensive and least effective option.  相似文献   

20.
城市社区高血压双向转诊路径的应用评价   总被引:2,自引:0,他引:2  
目的评价所建立的适合我国城市社区人群的高血压双向转诊路径的效果、效益、可行性和可推广性。方法采用非随机同期对照试验和个人深入访谈法,对所建立的双向转诊路径进行评价。结果实施高血压双向转诊路径可以缩短患者的就诊时间、降低再就诊率、节约医疗费用、提高患者的满意度、提高治疗效果并使服务具有连续性。结论高血压双向转诊路径确实是一个具有成本效益的疾病管理模式。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号